Mitomycin Medac (Mitomycin)

Mitomycin functions as a DNA cross‑linking alkylating agent. Inside bladder cells it creates covalent bonds between DNA bases, forming interstrand cross‑links that block replication and transcription. This interference halts cell division and triggers apoptosis, especially in rapidly proliferating urothelial tumor cells.

The dose of Mitomycin Medac is determined by the prescribing physician based on the patient’s clinical condition, bladder size, and treatment protocol. The healthcare professional selects the appropriate concentration and volume for each intravesical instillation, and dosing schedules may vary between treatment cycles.

Safety data for Mitomycin Medac in pregnancy and lactation are limited, and the drug is generally contraindicated. Because mitomycin can cross biological membranes and may affect fetal development, it should be avoided unless the potential benefit justifies the potential risk. Breastfeeding mothers should also refrain from use.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

The most common alternative for intravesical treatment of NMIBC is Bacillus Calmette‑Guérin (BCG) immunotherapy. While BCG stimulates an immune response, mitomycin provides direct cytotoxicity through DNA cross‑linking. Mitomycin is often chosen for patients who cannot tolerate BCG or when rapid tumor eradication is desired, but each agent has a distinct efficacy and side‑effect profile.

Mitomycin Medac should be stored at temperatures below 25 °C, protected from light, and kept in its original sealed container to avoid moisture exposure. Before use, the solution should be inspected for any discoloration or particulate matter, and handling should follow standard aseptic techniques to maintain sterility.

The product is given by intravesical instillation. After transurethral resection of bladder tumor, the prescribed volume of Mitomycin solution is introduced into the bladder via a catheter, retained for a specified dwell time (often 1–2 hours), and then drained. This local delivery maximizes bladder exposure while limiting systemic absorption.

Serious adverse events include myelosuppression, which can lead to severe infections or bleeding, and hemorrhagic cystitis, a potentially life‑threatening bladder bleeding. Renal toxicity and rare pulmonary fibrosis have also been reported. Patients should be monitored closely for blood count changes, urinary symptoms, and renal function during therapy.

Mitomycin Medac is contraindicated in individuals with known hypersensitivity to mitomycin or related compounds, severe renal impairment, active urinary tract infection, and in pregnant or breastfeeding women unless absolutely necessary. Patients with uncontrolled systemic illness or those receiving conflicting systemic chemotherapy should also avoid its use.